Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CTI-2 inhibits metastasis and epithelial-mesenchymal transition of breast cancer cells by modulating MAPK signaling pathway

ABSTRACT: CTI-2 inhibits metastasis and epithelial-mesenchymal transition of breast cancer cells by modulating MAPK signaling pathway

PROVIDER: PRJNA777825 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16770671_1.fastq.gz	Fastqsanger.gz
	SRR16770672_1.fastq.gz	Fastqsanger.gz
	SRR16770673_1.fastq.gz	Fastqsanger.gz
	SRR16770674_1.fastq.gz	Fastqsanger.gz
	SRR16770675_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

CTI-2 inhibits metastasis and epithelial-mesenchymal transition of breast cancer cells by modulating MAPK signaling pathway

Project description:Although some breast cancer patients die due to tumor metastasis rather than from the primary tumor, the molecular mechanism of metastasis remains unclear. Therefore, it is necessary to inhibit breast cancer metastasis during cancer treatment. In this case, after designing and synthesizing CTI-2, we found that CTI-2 treatment significantly reduced breast cancer cell metastasis in vivo and in vitro. Notably, with the treatment of CTI-2 in breast cancer cells, the expression level of E-cadherin increased, while the expression level of N-cadherin and vimentin decreased. In addition, after CTI-2 treatment, those outflow levels for p-ERK, p-p38, and p-JNK diminished, while no significant changes in the expression levels of ERK, JNK, or p38 were observed. Our conclusion suggested that CTI-2 inhibits the epithelial-mesenchymal transition (EMT) of breast carcinoma cells by inhibiting the activation of the mitogen-activated protein kinase (MAPK) signaling pathway, thereby inhibiting the metastasis of breast tumor cells. Therefore, we believe that CTI-2 is another candidate for breast tumor medication.

2021-11-06 | GSE188144 | GEO

CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway.

| S-EPMC8622910 | biostudies-literature

Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer

Project description:This SuperSeries is composed of the following subset Series: GSE29435: Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer: cell line data GSE29436: Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer: patient data Refer to individual Series

2012-01-26 | E-GEOD-29437 | biostudies-arrayexpress

Docetaxel inhibits epithelial-mesenchymal transition in human mammary cells

Project description:Docetaxel inhibits epithelial-mesenchymal transition in human mammary cells

| PRJNA1035779 | ENA

MAPK

Project description:MAPK

| PRJNA1054526 | ENA

PTEN phosphatase inhibits metastasis

Project description:PTEN phosphatase inhibits metastasis

| PRJNA865358 | ENA

LZTFL1 inhibits lung tumorigenesis by maintaining the differentiated state of lung epithelial cells and suppressing MAPK and SHH signaling pathways

Project description:Previously, we found that LZTFL1 is down-regulated in epithelial tumors including lung cancer and functions as a tumor suppressor in gastric cancers. However, the functional role of LZTFL1 in lung oncogenesis is undefined. We show here that downregulation of LZTFL1 expression in non-small cell lung cancer is associated with recurrence and poor survival, while re-expression of LZTFL1 in lung tumor cells inhibited extravasation/colonization of circulating tumor cells to the lung and inhibited tumor growth in vivo. Mechanistically, we found that LZTFL1 is expressed in ciliated human bronchial epithelial cells (HBECs) and its expression correlates with HBEC differentiation. LZTFL1 inhibits TGFÎ²-activated MAPK and hedgehog signaling. Alteration of intracellular levels of LZTFL1 resulted in changes of expression of genes associated with epithelial-to mesenchymal transition (EMT). We conclude that LZTFL1 inhibit lung tumorigenesis, possibly by maintaining epithelial cell differentiation and/or inhibition of signalings that lead to EMT, and suggest that reactivation of LZTFL1 expression in tumor cells may be a novel lung cancer therapeutic approach. Examination of the whole genome expression profiles of HCC95-GFP, HCC95GFP+TGFÎ²,HCC95-LZTFL1-GFP,HCC95-LZTFL1-GFP+TGFÎ², H460-GFP, and H460-LZTFL1-GFP cells

2015-12-31 | E-GEOD-70919 | biostudies-arrayexpress

The Role of KDM2A and H3K36me2 Demethylation in Modulating MAPK Signaling during Neurodevelopment.

Project description:The Role of KDM2A and H3K36me2 Demethylation in Modulating MAPK Signaling during Neurodevelopment.

| PRJNA956289 | ENA

Elf5 inhibits epithelial mesenchymal transition in development and cancer metastasis through transcriptional repression of Snail2

Project description:Elf5 inhibits epithelial mesenchymal transition in development and cancer metastasis through transcriptional repression of Snail2

| PRJNA147651 | ENA

SNX18 inhibits melanoma migration by modulating the activation ratio of Cdc42 & RhoA

Project description:SNX18 inhibits melanoma migration by modulating the activation ratio of Cdc42 & RhoA

| PRJNA491419 | ENA